Providers should consider the use of antiviral medications for the treatment and chemoprophylaxis of influenza as detailed in CDC’s Influenza Antiviral Medications: Summary for Clinicians.
Providers should continue to test for SARS-CoV-2; ideally, laboratory testing should be multiplex for both SARS-CoV-2 and influenza. Recommendations on treatment of COVID-19 can be found on our COVID-19 Therapeutic Recommendations page.
Current COVID-19 vaccination recommendations can be found at CDC’s Interim Clinical Considerations, Use of COVID-19 Vaccines in the United States. This guidance includes recent recommendations on the use of bivalent mRNA COVID-19 vaccine boosters for those 12 years and older. Additional authorizations for the use of bivalent boosters in younger ages are anticipated soon.
The Advisory Committee on Immunization Practices (ACIP) Influenza Vaccine Recommendations provides current recommendations for influenza vaccination. These include the new preferential recommendation for those > 65 years to receive either quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) whenever available.
We will be posting current data on influenza epidemiology on a weekly basis on the OCHCA Influenza page.